萬凱新材(301216.SZ):推動聚酯在新能源領域應用是公司研發和市場開拓重要方向之一
格隆匯5月18日丨有投資者在投資者互動平台向萬凱新材(301216.SZ)提問,“公司光伏新材料研發和生產方面目前取得哪些新進展?光伏新材料這塊是否是公司今後重點發展的方向?”
萬凱新材回覆稱,推動聚酯在新能源領域的應用是公司研發和市場開拓的重要方向之一,公司持續開展多維度的研發創新,着力於提升PET材料性能,拓展新的應用方向,着力於開發新型聚酯材料,開展生物基聚酯、化學法再生聚酯、高耐熱聚酯等技術的開發;形成基礎技術及產業化技術優勢,提升了公司產品及技術的市場競爭力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.